SCHEMBL25568624

SCHEMBL25568624

CC(C)(C)OC(=O)NC1(CCNC(=O)OCc2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 2/20 0.49
HTT P42858 1/20 0.48
IDO1 P14902 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KLK7 P49862 2/20 0.44
KLK5 Q9Y337 2/20 0.44
TGM2 P21980 1/20 0.44
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPFFR1 Q9GZQ6 1/20 0.43
NPFFR2 Q9Y5X5 1/20 0.43
KEAP1 Q14145 3/20 0.43
NFE2L2 Q16236 3/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14014439 0.93 MAPT (0.52) SYKLMNASMN1; SMN2MAPTHTT
SCHEMBL14014442 0.89 SYK (0.53) SYKLMNASMN1; SMN2MAPTHTT
SCHEMBL4549859 0.85 SYK (0.51) SYKLMNASMN1; SMN2MAPTHTT
SCHEMBL14737847 0.84 SYK (0.56) SYKLMNASMN1; SMN2MAPTHTT
SCHEMBL15202883 0.82 SYK (0.64) SYKLMNASMN1; SMN2MAPTHTT
SCHEMBL16839617 0.82 PPARA (0.50) SYKIDO1L3MBTL1KLK7KLK5
SCHEMBL15585054 0.82 SYK (0.48) SYKLMNASMN1; SMN2MAPTHTT
SCHEMBL31454371 0.80 SYK (0.53) SYKLMNASMN1; SMN2MAPTIDO1
SCHEMBL2722714 0.80 SYK (0.54) SYKLMNASMN1; SMN2MAPTIDO1
SCHEMBL31480812 0.80 SYK (0.51) SYKLMNASMN1; SMN2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091438-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS MERCK SHARP & DOHME LLC (US) 2023-05-25 WO disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TCOF1, SLC10A2, PAM SYK 567/4885LMNA 1047/4885SMN1; SMN2 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.